Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement
Matthew R. Reynolds, Yang Lei, Kaijun Wang, Khaja Chinnakondepalli, Katherine A. Vilain, Elizabeth A. Magnuson, Benjamin Z. Galper, Christopher U. Meduri, Suzanne V. Arnold, Suzanne J. Baron, Michael J. Reardon, David H. Adams, Jeffrey J. Popma, David J. Cohen and CoreValve U.S. High Risk Pivotal Trial Investigators
TAVR With a Self-Expanding Prosthesis Versus SAVR: Cost-Effectiveness Results
Mean incremental 12-month costs and benefits (TAVR – SAVR) are plotted on the cost-effectiveness plane with benefits expressed as QALY (A) or LY (B). Solid circles represent base case estimates, the surrounding open circles represent individual results for 1,000 replications of the study using bootstrap resampling, and the lines represent a willingness to pay threshold of $50,000 per QALY/LY gained (green) or $150,000 per QALY/LY gained (purple). For both effectiveness outcomes, the point estimates are near $50,000 per QALY/LY gained and ∼90% of replicates are below $150,000 per QALY/LY gained. See text and Table 3 for additional details. ICER = incremental cost-effectiveness ratio; LY = life-year(s); QALY = quality-adjusted life-year(s); SAVR = surgical aortic valve replacement; TAVR = transcatheter aortic valve replacement.